Posted inNews and Updates
Risvutatug Rezetecan Shows Survival Benefit in SCLC Trial
Hansoh Pharmaceutical’s HS-20093 met primary endpoints in the ARTEMIS-008 trial, showing significant survival benefits for patients with SCLC.
Posted inNews and Updates
AstraZeneca Trial Disappointment: What Investors Must Know
AstraZeneca’s latest clinical setback forces investors to rethink pharma valuation. Learn how R&D risks and pipeline diversity shape long-term stock value.
Posted inNews and Updates
New Shigella Vaccine Shows Strong Results in Phase 2 Trial
A new Phase 2 trial shows a promising Shigella vaccine induces a strong immune response, potentially offering a breakthrough against antibiotic-resistant bacteria.
Posted inNews and Updates
Amgen Faces Global Scrutiny Over Tavneos Safety Profile
Amgen is defending its vasculitis drug Tavneos amid global regulatory concerns over safety. Learn about the potential impact on clinical guidelines.
Posted inNews and Updates
Breakthrough Procedure Safely Treats Serious Twin Condition
A world-first study confirms a breakthrough procedure safely treats Twin-to-Twin Transfusion Syndrome, offering new hope for high-risk twin pregnancies.
Posted inNews and Updates
New Trial Design Speeds Up Early-Stage CAR-T Cancer Research
Innovative trial designs are set to accelerate early-stage CAR-T cancer research, improving safety protocols and speeding up the delivery of new therapies.
Posted inNews and Updates
Humanoid Robots Perform First Successful Live Gallbladder Surgery
Humanoid robots have successfully performed their first live gallbladder surgeries. Discover how this medical breakthrough is reshaping robotic surgery.
Posted inNews and Updates
FDA Clears FT839 CAR-T Therapy Trial for Autoimmune Diseases
The FDA has cleared Fate Therapeutics’ FT839 for clinical trials. Discover how this off-the-shelf CAR-T therapy aims to revolutionize autoimmune treatment.
Posted inNews and Updates
3 Psychedelic Stocks to Watch for Clinical Trial Milestones
Discover three psychedelic medicine companies nearing critical clinical trial data that could reshape mental health treatment and attract investor interest.
Posted inNews and Updates
AstraZeneca’s Wainua Misses Primary Goal in Heart Trial
AstraZeneca’s Wainua fails to meet primary endpoints in the CARDIO-TTRansform heart disease trial, prompting expert scrutiny over study design and efficacy.